E-Book 2nd Congress
- Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of Neisseria gonorrheae
-
Mohammad Reza Mohammadi,1,*
1. Department of Bacteriology, School of Medicine, Tarbiat Modares University,Tehran,Iran
- Introduction: Neisseria gonorrhea is a gram negative diplococci leads to sexually transmitted infection. Humans are the only known host of Neisseria gonorrhea. Gonococcus is not a normal flora but can cause asymptomatic infections, especially in women. In 2017, the World Health Organization published a list of 12 global priority pathogens with dental treatment options, including antibiotic-resistant N. gonorrhea.
- Methods: We review Zoliflodacin antibiotics, clinical trials, and their impact on human health using keywords such as Zoliflodacin , antibiotics, and neisseria from various data sources such as Pub-Med, and Science-Direct-Google-Scholar.
- Results: Zoliflodacin targets antibiotic-resistant gonorrhea. Zoliflodacin shows therapeutic approach against N. gonorrhea. It acts by inhibiting bacterial type 2 topoisomerase with binding site in bacterial gyrase. It shows promising results against N. gonorrhea. Zoliflodacin is effective in treating gonococcal urogenital and rectal infection.
- Conclusion: Antibiotic is the only option to treat N. gonorrhea. There is no vaccine available to treat gonorrhea. The new drug, zoliflodacin, specifically targets antibiotic-resistant gonorrhea. This is giving a hope to researchers. In this study, we elaborate the discovery of zoliflodacin, its mechanism of action, the current clinical trials, and the effectiveness of zoliflodacin
- Keywords: Neisseria gonorrhea, Zoliflodacin, Antibiotic-resistance, Treatment